Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum

Sponsor
Technical University of Munich
Study ID
NCT02733094
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Pyoderma Gangrenosum

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to explore the efficacy and safety of anti-Interleukin-(IL)17 therapy (secukinumab, administered weekly for 4 weeks followed by four-weekly administration until week 16) for the treatment of pyoderma gangrenosum.

Key Dates

Start date
Apr 30, 2016
Status verified
Feb 2020
Primary completion
Sep 10, 2019
Completion
Sep 19, 2019

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Open-label
    300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 2 weeks until week 32.

Primary Outcome Measure

Change of the Physician's global assessment [ Time Frame: Week 16 ]

Related Studies